Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) reported fourth-quarter fiscal 2026 revenue of $5.274 billion, with growth across all four continuing business segments. Revenue rose 5.4% year over year; GAAP diluted earnings per share increased 110.0% to $2.52, while adjusted EPS rose 27.3% to $4.15.
For the year ended September 30, revenue increased 4.9% to $19.5 billion. GAAP and adjusted diluted EPS were $5.06 and $12.70, respectively. Continuing operating cash flow rose 30.0% to $3.6 billion, and free cash flow increased 42.5% to $2.9 billion.
BD expects fiscal 2027 revenue growth in the low single digits and adjusted diluted EPS of $13.10–$13.30. It plans $19 billion of U.S. investment over several years under a government partnership. Results exclude the former Biosciences and Diagnostic Solutions business, whose spin-off and combination with Waters closed February 9, 2026.
BD (NYSE: BDX) raised its quarterly dividend to $1.06 per common share and authorized additional share repurchases.
The dividend is up 1.0% from the previous quarter and is payable December 31, 2026, to holders of record December 10, 2026. The indicated annual rate is $4.24 per share. The board authorized repurchases of up to 10 million additional shares, beyond shares remaining under its previous 2026 authorization.
BD (NYSE: BDX) appointed Bridget Bagnato worldwide president of its Peripheral Intervention business unit, effective November 16, 2026.
Based at the unit's headquarters in Tempe, Arizona, she will oversee its global strategic, operational and commercial performance and report to Peter Menziuso, executive vice president and president of the Interventional segment. Bagnato currently leads BD's Specimen Management business unit and has held leadership roles across the company during more than 27 years at BD.
BD (BDX) announced the U.S. commercial launch of its Liverty TIPS Stent Graft for patients with complications of portal hypertension. TIPS is a minimally invasive procedure that creates a new blood-flow pathway in the liver to relieve pressure.
BD says the system is designed to help physicians tailor treatment to individual anatomy and clinical needs. The launch is supported by six-month interim results from the prospective, multicenter ARCH study involving 177 patients; no numerical clinical outcomes were provided.
BD (BDX) will host an audio webcast on November 5, 2026, to discuss its fourth-quarter and full-year fiscal 2026 financial results.
The webcast begins at 8 a.m. ET and will include an operations and strategy update. The fiscal year ended September 30, 2026. BD will release financial information and presentation materials before the call on its investor relations website, where a replay will also be available.
BD (NYSE: BDX) joined the Global Surgery Foundation and Business Council for International Understanding to convene a maternal-safety panel on September 24.
Held at the Japan Society alongside the 81st United Nations General Assembly, the discussion explored continuous noninvasive blood pressure monitoring and other measures of blood circulation to help clinicians recognize childbirth complications earlier. Participants called for broader adoption of evidence-based maternal care and improved monitoring standards. The discussion addressed progress toward the UN goal of fewer than 70 maternal deaths per 100,000 live births by 2030.
BD (NYSE: BDX) announced nine-month AGILITY trial results showing its Revello Vascular Covered Stent met the primary endpoint in iliac artery disease.
The cohort enrolled 120 patients at 28 sites. The combined safety and effectiveness endpoint had a 2.8% failure rate, significantly below the prespecified 19% performance goal. Primary patency, meaning treated arteries remained open, was 97.2%; freedom from clinically driven repeat treatment of the target lesion was 98.3%. There were no device- or procedure-related deaths, target limb major amputations or unanticipated serious adverse device effects. Mean Rutherford disease-severity category improved from 3.0 to 0.3, and the mean walking impairment questionnaire score rose 31.7 points from baseline.
Follow-up continues through 36 months. Enrollment in a separate leg-artery cohort finished in August. Revello is CE marked but remains limited to investigational use in the United States.
BD (BDX) marked 65 years of manufacturing at its Canaan, Connecticut, facility, which produces more than 2 billion syringes annually.
The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. Today, more than 500 employees work at the 385,000-square-foot facility. BD has invested more than $34 million over the past five years to expand production capacity, modernize operations and support future growth, including three new syringe manufacturing lines and equipment upgrades.
As part of the celebration, BD will announce a $10,000 grant to the Community Health & Wellness Center. The grant brings its support since 2024 to $90,000, helping fund nutrition programs, emergency assistance and patient transportation.
BD (BDX) has appointed Ferass Abuzaina worldwide president of its Surgery business unit, effective immediately, to oversee its global performance. His responsibilities cover strategy, operations and commercial performance. He will be based at Surgery's headquarters in Warwick, Rhode Island, and report to Peter Menziuso, executive vice president and president of the Interventional segment.
Abuzaina currently serves as worldwide vice president and general manager of Advanced Repair and Reconstruction within Surgery. He joined BD in 2013 and has held leadership roles across multiple businesses, with experience in research and development, strategy and business development.
BD (BDX) announced a partnership with the U.S. Government to expand domestic manufacturing and production of essential medical consumables. BD intends to invest $19 billion in the U.S. over several years, including capital, operational and supply chain investments. Of that amount, $3 billion is intended for U.S. manufacturing expansion.
BD plans to expand end-to-end U.S. production by approximately 5 billion consumables annually, raising its domestically supplied share to roughly 80 percent, and manufacture 100 percent of its needles used in America domestically using American-made steel. The agreement provides relief from future Section 232 tariffs on covered products and inputs, subject to the final scope and implementation of those actions and achievement of agreed milestones. Final tariff rates, product scope and timing remain undetermined; BD is not currently quantifying the financial impact.